Lanadelumab

  • Part D specialty tier in 90% of formularies (2026Q3)
  • Biologic
  • TAKHZYRO

Therapy management checklist

Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.

Loading the therapy management checklist…

Storage and cold chain

Lanadelumab: storage and handling

Refrigerate
Yes, as the label states
Label statement
Store the prefilled syringes refrigerated at 36°F to 46°F (2°C to 8°C).
Freezing
Do not freeze
Label statement
Do not freeze.
Room temperature
No allowance stated
Back into the refrigerator
Not addressed
Light
Protect from light
Label statement
Keep the prefilled syringe in the original carton to protect from light.
Shaking
Do not shake
Label statement
Do not shake.

Temperature excursion helper

Answers only from this label's storage statements. It does not judge whether a product is still usable beyond what the label states.

The label does not state a room-temperature allowance for this product.

Entered: 1 day at up to 77°F (25°C).

Store the prefilled syringes refrigerated at 36°F to 46°F (2°C to 8°C).
Do not freeze.

Contact the manufacturer at 1-877-TAKEDA-7 (1-877-825-3327) (the number printed on the label) about this product.

Where the label prints this number
Questions? For product or service-related questions, call 1-877-TAKEDA-7 (1-877-825-3327) or go to www.TAKHZYRO.com .
All storage statements on the label (11)
  • Store the prefilled syringes refrigerated at 36°F to 46°F (2°C to 8°C).
  • Do not freeze.
  • Do not shake.
  • Keep the prefilled syringe in the original carton to protect from light.
  • Storing TAKHZYRO: Store the TAKHZYRO prefilled syringe in the refrigerator between 36°F to 46°F (2°C to 8°C).
  • Store the TAKHZYRO prefilled syringe in the original carton to protect it from light.
  • Throw away (discard) the TAKHZYRO prefilled syringe if it has been kept out of the refrigerator, frozen, or not kept in the original carton protected from light.
  • Do not shake the TAKHZYRO prefilled syringe.
  • Remove the TAKHZYRO prefilled syringe carton from the refrigerator 15 minutes before injecting.
  • Your medicine is sensitive to warm temperatures .
  • Do not use heat sources such as a microwave or hot water to warm your TAKHZYRO prefilled syringe. c.

FDA label version 16, effective August 26, 2026. DailyMed

Dosing and titration calendar

Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.

Loading dosing schedules…

Medicare Part D coverage

7%of plans list it
69%of those: prior authorization
0%step therapy
41%quantity limit
99%specialty tier

5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan

Patient assistance

No manufacturer program page is listed for this drug yet.

Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.

For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.